The critical roles of MDM2 and MDM4 as negative modulators of p53, which have been elegantly established using knock-out models [20], [21], as well as the over-expression of these proteins in several cancer types [17], [22], [23] raised expectations on the therapeutic potential of restoring p53 functions by MDM2/4 in tumors. The gene discussed is TP53; the disease is cancer.